- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Sotera Health Reports Revenue Growth and Margin Expansion in 2025
Company outlines expectations for continued growth and higher earnings in 2026.
Published on Feb. 27, 2026
Got story updates? Submit your updates here. ›
Sotera Health (NASDAQ:SHC) reported revenue growth of 5.7% in 2025 to $1.164 billion, or 5.2% on a constant-currency basis. Adjusted EBITDA rose 8.2% (7.8% constant currency) to $593.8 million, and adjusted EBITDA margin expanded to 51%, an increase of roughly 120 basis points year over year. The company also reported adjusted free cash flow of more than $200 million for the year.
Why it matters
Sotera Health's strong financial performance in 2025, including revenue growth, margin expansion, and robust free cash flow, demonstrates the company's ability to execute its long-term strategy and capitalize on growth opportunities in the sterilization and laboratory testing services market. The company's guidance for continued growth in 2026 further reinforces its position as a leading provider of critical services to the medical device, pharmaceutical, and other industries.
The details
In the fourth quarter, Sotera Health reported revenue of $303 million, up 4.6% year over year (2.5% constant currency). Adjusted EBITDA increased 2.7% to $157 million, with adjusted EBITDA margin of 51.8%. The company highlighted several 2025 operational milestones, including customer satisfaction exceeding 80% and cross-business-unit customer revenue growth of 9% year over year. Sterigenics delivered roughly 8% constant-currency revenue growth, Nordion delivered about 9% constant-currency revenue growth, and Nelson Labs achieved core lab testing growth and expanded margins by 312 basis points.
- Sotera Health reported its Q4 2025 and full-year 2025 results on February 27, 2026.
The players
Sotera Health
A global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries.
Michael Petras
Chairman and CEO of Sotera Health.
Jon Lyons
CFO of Sotera Health.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”
— Gordon Edgar, grocery employee (Instagram)
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.
Jacksonville top stories
Jacksonville events
Mar. 10, 2026
Moulin Rouge! The Musical (Touring)Mar. 11, 2026
Moulin Rouge! The Musical (Touring)Mar. 12, 2026
Moulin Rouge! The Musical (Touring)




